In:
Molecular Oncology, Wiley, Vol. 9, No. 1 ( 2015-01), p. 128-139
Kurzfassung:
The first clinical study exploring metabolomics in predicting breast cancer relapse. A serum‐derived signature predicted relapse (90% sensitivity, 67% specificity). In a multivariate the metabolomic signature maintained its prognostic value.
Materialart:
Online-Ressource
ISSN:
1574-7891
,
1878-0261
DOI:
10.1016/j.molonc.2014.07.012
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
2322586-5